Massachusetts Patent of the Month – February 2025
Atea Pharmaceuticals has developed an innovative oral antiviral treatment effective against SARS-CoV-2 (COVID-19) and other coronaviruses. At the heart of this advancement is Compound 1, a purine nucleotide analog designed to block viral replication by targeting the RNA-dependent RNA polymerase (RdRp)—a critical enzyme for coronavirus spread.
Key Benefits of Atea’s Antiviral Treatment
• Oral Dosage for Home Use – Unlike injectable COVID-19 treatments requiring hospitalization, Atea’s pill offers convenient at-home care.
• Strong Antiviral Activity – Proven effective in human airway epithelial cells, where coronaviruses thrive.
• Targeted Lung Delivery – The active metabolite accumulates in lung tissue, the primary infection site, while minimizing exposure to other organs.
• Long-Lasting Protection – With an extended intracellular half-life, Compound 1 maintains therapeutic levels longer, aiding early intervention.
• Broad-Spectrum Potential – Effective against multiple coronaviruses, including HCoV-229E and HCoV-OC43, making it a vital tool against future variants.
Why This Matters for COVID-19 & Future Pandemics
As new coronavirus variants emerge, Atea’s versatile antiviral platform provides a critical line of defense. By disrupting viral replication early, this treatment could reduce severe complications and help control outbreaks more efficiently.
Atea Pharmaceuticals is revolutionizing antiviral therapy, offering a safer, more accessible solution to combat COVID-19 and beyond.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
